Trials / Completed
CompletedNCT01007448
Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL)
Phase IV Randomized Study of Two Dose Levels of Targretin® Capsules in Subjects With Refractory Cutaneous T-Cell Lymphoma
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 59 (actual)
- Sponsor
- Bausch Health Americas, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, randomized, open-label, Phase IV study to assess the efficacy, tolerability, and safety of 2 initial dose levels of bexarotene capsules in participants with refractory CTCL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bexarotene | Soft gelatin capsules to be taken orally with at least 6 ounces of water or other fluid either with or immediately following the evening meal (a moderate or full meal) or a nutritionally defined liquid food. |
Timeline
- Start date
- 2010-01-06
- Primary completion
- 2014-02-20
- Completion
- 2014-02-20
- First posted
- 2009-11-04
- Last updated
- 2019-11-12
- Results posted
- 2019-11-12
Locations
17 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01007448. Inclusion in this directory is not an endorsement.